Загрузка...
Ibrutinib and novel BTK inhibitors in clinical development
Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has eme...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2013
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3751776/ https://ncbi.nlm.nih.gov/pubmed/23958373 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-59 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|